Book a demo

Cut patent&paper research from weeks to hours with PatSnap Eureka AI!

Try now
Azurity Pharmaceuticals et al. v. Accord Healthcare | Patent Lawsuit 1:23-cv-00373

Azurity Pharmaceuticals, Inc. et al. v. Accord Healthcare, Inc.

1:23-cv-00373 D. Del. Closed US9050307B2
Get a prior-art report

Infringement action filed 31 Mar 2023 in the United States District Court for the District of Delaware and closed 21 Jun 2023, with US9050307B2 asserted. Recorded basis of termination: voluntary dismissal.

Case recordPatsnap Litigation Data·

Case record

Patent involved
US9050307B2
Application no.
US14/003598
Case no.
1:23-cv-00373
Verdict cause
Infringement action
Court
D. Del.
Court level
District Court
Case region
Delaware
Chief judge
Colm F. Connolly
Trial level
First instance
Filed – Closed
31 Mar 2023 – 21 Jun 2023
Duration
82 days
Basis of termination
Voluntary dismissal
Products & marks
Method for the preparation of a levothyroxine solution
Validity challenges
None recorded
Source: Patsnap Litigation Data. Case 1:23-cv-00373, United States District Court for the District of Delaware. Open this record in Eureka
Patsnap Eureka

Check this patent against your own product

Prior art, claim scope, infringement exposure and design-around routes. Every answer cites the records behind it.

Get an FTO claim chart
10,000 free credits to start
Patent at issue
US9050307B2 Active App. US14/003598

Method for the preparation of a levothyroxine solution

Levothyroxine, also known as L-thyroxine, synthetic T4, or 3,5,3′,5′-tetraiodo-L-thyronine, CAS number 51-48-9, is a synthetic form of thyroxine, used as a hormone substitute for patients with thyroid conditions. The invention relates to a method for the preparation of an oral levothyroxine composition. The method according to the invention results in liquid levothyroxine formulations that have improved storage stability compared to known liquid levothyroxine formulations.

Read claims and description in Eureka
Patent standing
Legal status
Active
Granted
9 Jun 2015
Est. expiry
6 Aug 2031
Validity challenges
None recorded
Licences recorded
None recorded
Classification
A61K31/198A61K9/08A61K31/055
Examiner
BASQUILL, SEAN
Source: Patsnap patent data + case record. Bibliographic fields and drawings reproduced from the published patent document. Break down the claims
Parties & counsel

Parties of record

Counsel of record

Source: case record + Patsnap company data. Attorney names appear as recorded in the docket. Compare both portfolios
Outcome

Basis of termination

From the record · verbatim

“Pursuant to Rule 41(a)(1)(A)(i) of the Federal Rules of Civil Procedure, Plaintiffs Azurity Pharmaceuticals, Inc. and EMP Levo US, B.V. hereby dismiss all claims asserted in this action without prejudice. At the time of filing this Notice of Dismissal, Defendant Accord Healthcare, Inc. has not served an answer or motion for summary judgment in this matter.”

Case 1:23-cv-00373 · D. Del. · closed 21 June 2023
Source: case record, verbatim. The quoted paragraph is the basis-of-termination text as filed.

Related cases

Three questions this record usually leads to. Each one runs against the full litigation and patent corpus, and cites what it finds.

FAQ

Frequently asked questions

What is case 1:23-cv-00373?

1:23-cv-00373 is a patent infringement action brought by Azurity Pharmaceuticals, Inc. against Accord Healthcare, Inc., filed on 31 Mar 2023 in the United States District Court for the District of Delaware. The case closed on 21 June 2023.

Which patent was asserted in 1:23-cv-00373?

US9050307B2 (“Method for the preparation of a levothyroxine solution”), assigned to EMP LEVO US B.V., currently active. The record also lists Method for the preparation of a levothyroxine solution.

How was case 1:23-cv-00373 terminated?

The recorded basis of termination is voluntary dismissal. The termination text reads: “Pursuant to Rule 41(a)(1)(A)(i) of the Federal Rules of Civil Procedure, Plaintiffs Azurity Pharmaceuticals, Inc. and EMP Levo US, B.V. hereby dismiss all claims asserted in this action without prejudice. At the time of filing this Notice of Dismissal, Defendant Accord Healthcare, Inc. has not served an answer or motion for summary judgment in this matter.”

What does dismissal without prejudice mean?

A dismissal without prejudice ends this action but leaves the claims alive — the plaintiff may file them again later, subject to the limitation period.

How long did case 1:23-cv-00373 take?

82 calendar days, from filing on 31 Mar 2023 to closure on 21 June 2023.

Who were the attorneys and the judge in 1:23-cv-00373?

Chief Judge Colm F. Connolly presided. Ian Robert Liston, Jennifer A. Ward, Jody Karol, Kristina M. Hanson and Wendy L. Devine are recorded as counsel for plaintiff Azurity Pharmaceuticals.

Answers reproduce fields from the case record for 1:23-cv-00373 and do not constitute legal advice. Ask your own question

Disclaimer. This page reproduces publicly available court docket data for case 1:23-cv-00373 and is provided for general information and reference only. It is not legal advice and must not be relied upon as such.

Docket data has limits. Records are drawn from a snapshot and may lag the live docket. Sealed filings, amended complaints, counterclaims and post-closure motions may not be reflected. Party names, attorney names and firm affiliations are reproduced as recorded and may contain omissions. Where a field is absent from the record, this page marks it as not recorded rather than inferring a value.

No characterisation of the parties or the outcome. This page reports what the record contains. Nothing here should be read as an assertion that any party infringed, that any patent is valid or invalid, that any settlement occurred, or that any party prevailed.

No FTO or validity opinion. Nothing on this page constitutes a freedom-to-operate, novelty, validity or infringement opinion. Any decision touching a live patent dispute should be verified independently and reviewed with qualified patent counsel.

Related Litigation Cases

Help us improve this page

Found incorrect or outdated information? Let us know and we'll get it fixed.